WorldStar Winner: Instanyl DoseGuard Nasal Spray Device

WINNERS 2024

Disclaimer:
-The image and text displayed in the blue box have been provided directly by the applicant of WorldStar.
-This information, including the submitted images, is the sole responsibility of the respective company.
-WPO and WorldStar do not assume any liability for the accuracy or content of the provided information.
-By submitting their entry, the applicants grant WPO permission to publish these details upon winning.

Instanyl DoseGuard Nasal Spray Device

Company:

Takeda Pharmaceuticals, Aptar Pharma

www.takeda.com

Country: USA

Category: Medical and Pharmaceutical

The Instanyl DoseGuard is a novel electronic nasal lockout device developed by Takeda and Aptar. The Instanyl DoseGuard nasal spray primary packaging device has been developed to manage breakthrough pain in adults already using a controlled drug substance to control long-term cancer pain. The aim of the Instanyl DoseGuard is to safeguard patients and others from the risk of overdose, misuse, abuse, addiction, diversion, accidental exposure, and medication errors. Instanyl DoseGuard the first electronic nasal lockout device approved by a Notified Body and EMA for Takeda Pharmaceuticals International AG. It limits the number of doses a patient can take within the prescribed dosing regime and automatically locks after delivering two doses within an hour, thus preventing overuse and misuse. The number of remaining doses is displayed to assist the patient with adherence and has a child-resistant cap for added safety. The device has been validated for HumanFactors in accordance with

Read More

IEC 62336, confirming the ergonomic design is user-friendly for senior patients, with adequate finger-space, a color-distinguished nozzle, and an easy to hold overall grip. Aesthetically, the design semantics improve the mature drug administration to prevent and avoid potential misuse.

The Instanyl DoseGuard demonstrates how a primary packaging device can be leveraged to address safety and regulatory issues responsibly for the benefit of patients and the community at large. It demonstrates the multifunctionality of an innovative new design, including the use of materials, manufacturing technology, and electronics to provide a new generation of device to an existing product platform. To minimize the carbon footprint, the product’s fully recyclable packaging is printed digitally. A take-back program has been established for the Instanyl DoseGuard device to ensure efficient recycling.
The Instanyl DoseGuard is a prime example of how design collaboration between pharmaceuticals, devices, and packaging can lead to innovative solutions that benefit patients.

Read Less